ASX Event Portfolio

21 Jan 2022
Latest update - 21 January 2022.

Minimum Investment Amount and Period

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32.

Period

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source. Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32.

Stock codeStock nameSectorCurrent priceReturn 12mMom rank
NVDA
NVIDIA Corp
Information Technology
$549.46214.71%
1
AMD
Advanced Micro Devices Inc
Information Technology
$84.48199.75%
2
DXCM
DexCom Inc
Health Care
$374.89177.95%
3
ETSY
Etsy Inc
Consumer Discretionary
$134.56144.28%
4
AAPL
Apple Inc
Information Technology
$113.16113.35%
5
REGN
Regeneron Pharmaceuticals Inc
Health Care
$581.64107.25%
6
SWKS
Skyworks Solutions Inc
Information Technology
$147.27101.64%
7
WST
West Pharmaceutical Services I
Health Care
$290.33100.43%
8
NOW
ServiceNow Inc
Information Technology
$491.5499.52%
9
PYPL
PayPal Holdings Inc
Information Technology
$191.6697.47%
10
NFLX
Netflix Inc
Communication Services
$505.8796.81%
11
QRVO
Qorvo Inc
Information Technology
$131.0889.28%
12
AMZN
Amazon.com Inc
Consumer Discretionary
$3,099.9688.02%
13
ADBE
Adobe Inc
Information Technology
$478.9887.32%
14
CTLT
Catalent Inc
Health Care
$88.8583.45%
15

Important notice:

Quantities and calculations in this post use our investment team’s model and might differ from yours. This post does not constitute an invitation to buy or sell any securities. Before conducting any transaction, make sure you fully understand the terms of the product and the relevant risk factors involved. You can seek professional advice to determine the appropriateness and cost of any transaction from the broker you use.

SHOW COMMENTS / QUESTIONS (4)

4
Comments

You need to be a Premium user to comment on this post. Click here and become premium now!

Graeme S.

Hi Shannon. I placed a Buy order for LNK at 5.51 on 23 Dec soon after the recommendation appeared. My order has not been filled as the price has remained above 5.51 since then and is now well above 5.51. What do you recommend?

Shannon Rivkin

Hi Graeme,
The jump in the LNK price has been frustrating as I want to buy this one for an attractive annualised arbitrage (given the protracted sales process and the likelihood that this is the best deal on the table). Let’s see where the price settles in the next week or so and hopefully we can get it a little cheaper than the last close of $5.57.
Regards,
Shannon

Anthony D.

Hi Shannon, I note that ZEL has dropped another 6 cents this morning. Do you see this as a potential indicator of bad news on the horizon for this takeover, or is there amore benign explanation, such as an adverse currency move or simply holders taking a profit?

On the other hand, does it present an opportunity to buy into this takeover at a very attractive price?

Shannon Rivkin

Hi Anthony, The NZ competition regulator released its preliminary statement of concerns which had a few red flags, hence the selling today. On further reading, the concerns seem easily addressed by Ampol (ALD) and are only in relation to ALD parting with its NZ division by IPO rather than trade sale. Effectively, the concern is that ALD will still have a degree of control through an IPO based on retained shareholding or agreements, so it seems an easy concession for ALD to make to commit to a trade sale or agree to a small shareholding with no commercial agreements post… Read more »

We are glad you liked it

For your convenience, this will appear under your Saved articles in the top menu.